Form 8-K - Current report:
SEC Accession No. 0001493152-23-010311
Filing Date
2023-03-31
Accepted
2023-03-31 16:22:55
Documents
16
Period of Report
2023-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41878
2 ex1-1.htm EX-1.1 324081
3 ex5-1.htm EX-5.1 16525
4 ex5-1_001.jpg GRAPHIC 1609
5 ex5-1_002.jpg GRAPHIC 3354
  Complete submission text file 0001493152-23-010311.txt   647550

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dare-20230331.xsd EX-101.SCH 3245
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dare-20230331_lab.xml EX-101.LAB 34916
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dare-20230331_pre.xml EX-101.PRE 22801
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3737
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 23788090
SIC: 2834 Pharmaceutical Preparations